🚀 VC round data is live in beta, check it out!
West Pharma Valuation Multiples
Discover revenue and EBITDA valuation multiples for West Pharma and similar public comparables like Straumann Group, Terumo, Smith & Nephew, Fresenius Medical Care and more.
West Pharma Overview
About West Pharma
West Pharmaceutical Services is based in Pennsylvania and is a key supplier to firms in the pharmaceutical, biotechnology, and generic drug industries. West sells elastomer-based packaging components (including stoppers, seals, and plungers), nonglass containment solutions, and auto-injectors for injectable drugs, which include large-molecule biologics, peptides such as GLP-1 receptor agonists, and small-molecule drugs. The company reports in two segments: proprietary products (about 80% of total revenue) and contract-manufactured products (about 20% of total revenue). It generates approximately 55% of its revenue from international markets and 45% from the United States.
Founded
1923
HQ
Employees
10.8K
Website
Sectors
Financials (LTM)
EV
$18B
West Pharma Financials
West Pharma reported last 12-month revenue of $3B and EBITDA of $807M.
In the same LTM period, West Pharma generated $1B in gross profit, $807M in EBITDA, and $542M in net income.
Revenue (LTM)
West Pharma P&L
In the most recent fiscal year, West Pharma reported revenue of $3B and EBITDA of $785M.
West Pharma expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $3B | XXX | $3B | XXX | XXX | XXX |
| Gross Profit | $1B | XXX | $1B | XXX | XXX | XXX |
| Gross Margin | 36% | XXX | 36% | XXX | XXX | XXX |
| EBITDA | $807M | XXX | $785M | XXX | XXX | XXX |
| EBITDA Margin | 26% | XXX | 26% | XXX | XXX | XXX |
| EBIT Margin | 21% | XXX | 21% | XXX | XXX | XXX |
| Net Profit | $542M | XXX | $530M | XXX | XXX | XXX |
| Net Margin | 17% | XXX | 17% | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
West Pharma Stock Performance
West Pharma has current market cap of $18B, and enterprise value of $18B.
Market Cap Evolution
West Pharma's stock price is $251.25.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $18B | $18B | 0.0% | XXX | XXX | XXX | $7.36 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialWest Pharma Valuation Multiples
West Pharma trades at 5.7x EV/Revenue multiple, and 21.9x EV/EBITDA.
EV / Revenue (LTM)
West Pharma Financial Valuation Multiples
As of March 28, 2026, West Pharma has market cap of $18B and EV of $18B.
Equity research analysts estimate West Pharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
West Pharma has a P/E ratio of 33.4x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $18B | XXX | $18B | XXX | XXX | XXX |
| EV (current) | $18B | XXX | $18B | XXX | XXX | XXX |
| EV/Revenue | 5.7x | XXX | 5.7x | XXX | XXX | XXX |
| EV/EBITDA | 21.9x | XXX | 22.4x | XXX | XXX | XXX |
| EV/EBIT | 27.5x | XXX | 27.7x | XXX | XXX | XXX |
| EV/Gross Profit | 15.6x | XXX | 16.0x | XXX | XXX | XXX |
| P/E | 33.4x | XXX | 34.1x | XXX | XXX | XXX |
| EV/FCF | 37.7x | XXX | 37.6x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified West Pharma Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
West Pharma Margins & Growth Rates
West Pharma's revenue in the last 12 month grew by 6%.
West Pharma's revenue per employee in the last FY averaged $0.3M.
West Pharma's rule of 40 is 32% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
West Pharma's rule of X is 40% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
West Pharma Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 6% | XXX | 6% | XXX | XXX | XXX |
| EBITDA Margin | 26% | XXX | 26% | XXX | XXX | XXX |
| EBITDA Growth | 11% | XXX | 12% | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 32% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 40% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.3M | XXX | XXX | XXX |
| S&M Expenses to Revenue | 13% | XXX | — | XXX | XXX | XXX |
| R&D Expenses to Revenue | 3% | XXX | 2% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 15% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
West Pharma Public Comps
See public comps and valuation multiples for other Medical Supplies comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Straumann Group | XXX | XXX | XXX | XXX | XXX | XXX |
| Terumo | XXX | XXX | XXX | XXX | XXX | XXX |
| Smith & Nephew | XXX | XXX | XXX | XXX | XXX | XXX |
| Fresenius Medical Care | XXX | XXX | XXX | XXX | XXX | XXX |
| Steris | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
West Pharma M&A Activity
West Pharma acquired XXX companies to date.
Last acquisition by West Pharma was on XXXXXXXX, XXXXX. West Pharma acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by West Pharma
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialWest Pharma Investment Activity
West Pharma invested in XXX companies to date.
West Pharma made its latest investment on XXXXXXXX, XXXXX. West Pharma invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by West Pharma
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout West Pharma
| When was West Pharma founded? | West Pharma was founded in 1923. |
| Where is West Pharma headquartered? | West Pharma is headquartered in United States. |
| How many employees does West Pharma have? | As of today, West Pharma has over 10K employees. |
| Who is the CEO of West Pharma? | West Pharma's CEO is Eric Mark Green. |
| Is West Pharma publicly listed? | Yes, West Pharma is a public company listed on NYSE. |
| What is the stock symbol of West Pharma? | West Pharma trades under WST ticker. |
| When did West Pharma go public? | West Pharma went public in 1973. |
| Who are competitors of West Pharma? | West Pharma main competitors are Straumann Group, Terumo, Smith & Nephew, Fresenius Medical Care. |
| What is the current market cap of West Pharma? | West Pharma's current market cap is $18B. |
| What is the current revenue of West Pharma? | West Pharma's last 12 months revenue is $3B. |
| What is the current revenue growth of West Pharma? | West Pharma revenue growth (NTM/LTM) is 6%. |
| What is the current EV/Revenue multiple of West Pharma? | Current revenue multiple of West Pharma is 5.7x. |
| Is West Pharma profitable? | Yes, West Pharma is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of West Pharma? | West Pharma's last 12 months EBITDA is $807M. |
| What is West Pharma's EBITDA margin? | West Pharma's last 12 months EBITDA margin is 26%. |
| What is the current EV/EBITDA multiple of West Pharma? | Current EBITDA multiple of West Pharma is 21.9x. |
| What is the current FCF of West Pharma? | West Pharma's last 12 months FCF is $467M. |
| What is West Pharma's FCF margin? | West Pharma's last 12 months FCF margin is 15%. |
| What is the current EV/FCF multiple of West Pharma? | Current FCF multiple of West Pharma is 37.7x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.